The Full Picture of Resmetirom (Rezdiffra) Approval: Deep Dive into MAESTRO-NASH Clinical Data

Introduction

On March 14, 2024, Madrigal Pharmaceuticals' Thyroid Hormone Receptor beta (THR-β) agonist, Resmetirom (Brand name: Rezdiffra), received accelerated approval from the US FDA as the world's first treatment for MASH (Metabolic dysfunction-associated steatohepatitis, formerly NASH). (Note: Following the 2023 multi-society consensus, NAFLD/NASH nomenclature was updated to MASLD/MASH. This article uses "MASH" except when referring to historical trial names).

This approval marks a monumental milestone, decisively ending the "winter era of MASH drug discovery," a period characterized by numerous high-profile late-stage pipeline failures. However, Resmetirom is not a "magic bullet" that completely cures all MASH patients. For all future MASH therapies in development, Resmetirom's clinical data has established the "absolute benchmark" that must be overcome.

This article dissects the detailed data (efficacy, baseline patient characteristics, and safety) from the pivotal Phase 3 clinical trial, "MAESTRO-NASH," explaining its clinical value and limitations.

1. MAESTRO-NASH Trial Overview and Baseline Characteristics

The MAESTRO-NASH trial was a 52-week, multi-center, double-blind, placebo-controlled Phase 3 study involving 966 adult patients with biopsy-confirmed MASH and moderate to advanced liver fibrosis (Stages F2 and F3)¹.

Baseline Patient Demographics

Average Age: ~56 years
Median BMI: ~35 (indicative of severe obesity)
Type 2 Diabetes (T2D) Comorbidity: ~67% (a majority of subjects had underlying T2D)
Fibrosis Stage Distribution: F3 was roughly 62-65%, F2 was ~30%, and a small minority were F1B.
- Note: This heavily "F3-dominant" population has significant implications for understanding the efficacy results.

2. Achievement of Co-primary Endpoints

The FDA set exceptionally high hurdles for MASH drug approval, requiring candidates to meet one or both of two co-primary endpoints. In the MAESTRO-NASH trial, Resmetirom successfully achieved both with resounding statistical significance.

Endpoint 1: NASH Resolution without worsening of fibrosis

Defined as an improvement in ballooning and inflammation (NAS score) with no worsening of the fibrosis stage.

Placebo group: 9.7%
Resmetirom 80mg group: 25.9% (p<0.001)
Resmetirom 100mg group: 29.9% (p<0.001)

👉 Deeper Dive into MoA: Resmetirom exhibits approximately 28-fold higher selectivity for THR-β over THR-α, purposefully avoiding the cardiotoxicity and bone toxicity associated with THR-α activation. Furthermore, its exclusive hepatic targeting is driven by robust uptake via hepatocyte OATP transporters (OATP1B1/1B3) combined with high plasma protein binding. Intracellularly, it downregulates de novo lipogenesis (DNL), upregulates fatty acid β-oxidation, and increases CYP7A1-mediated bile acid synthesis (lowering LDL-C). This clears lipotoxicity rapidly, targeting the root of ballooning and steatosis.

Endpoint 2: Fibrosis improvement by $\ge$1 stage without worsening of NAS

Defined as the regression (reversal) of existing fibrosis by at least one stage, without any worsening of the NAFLD Activity Score.

Placebo group: 14.2%
Resmetirom 80mg group: 24.2% (p<0.001)
Resmetirom 100mg group: 25.9% (p<0.001)

👉 Analysis: Resmetirom also showed a clear, statistically significant improvement in fibrosis compared to placebo. However, the sobering reality is that an improvement in ~25% of patients means that for the remaining ~75% of patients, preexisting F2/F3 fibrosis did not improve (remaining stagnant or worsening). This limitation is exactly why the industry is now aggressively pursuing next-generation "direct liver anti-fibrotics."

3. Crucial Secondary Endpoints: MRI-PDFF and LDL-C Reduction

Drastic Reductions in Hepatic Fat (MRI-PDFF)

In both the MAESTRO-NASH and its sister trial MAESTRO-NAFLD-1, Resmetirom induced massive reductions in hepatic fat fraction measured by MRI-PDFF:

Week 16: -34.9% (80mg) and -38.6% (100mg) vs. placebo.
Week 52: -28.8% (80mg) and -33.9% (100mg). A $\ge$30% relative reduction in MRI-PDFF is highly regarded by the FDA and the industry as a robust surrogate marker for histological clinical efficacy in MASH.

LDL Cholesterol Reduction

Another profoundly important clinical benefit is its impact on lipid profiles. The leading cause of death in MASH patients is Cardiovascular Disease (CVD), not liver failure.

At week 24, Resmetirom significantly reduced LDL cholesterol by approximately 13-16% from baseline (while the placebo group saw virtually no change). This dual-action profile—"improving liver pathology while simultaneously lowering cardiovascular risk (lipids)"—was a major factor in securing positive FDA reception.

4. Safety and Tolerability Profile

For any approved life-long medication, safety and tolerability are just as critical as efficacy.

Primary Adverse Events (Side Effects)

Resmetirom was generally well-tolerated, but distinct gastrointestinal side effects were noted.

Diarrhea: 28% in the 80mg group, 33% in the 100mg group (vs. 16% for placebo). This typically occurred during the early weeks of treatment and tended to resolve over time.
Nausea: ~22% in both treatment groups (vs. 13% for placebo).

Notable Safety Advantages

Weight-Independent Efficacy: Unlike GLP-1 agonists (e.g., Semaglutide) and FGF21 analogues, Resmetirom achieves MASH resolution and fibrosis reversal without inducing significant systemic weight loss. This positions it distinctly as a direct metabolic liver modifier.
Thyroid Axis Changes: While transient and mild fluctuations in TSH and free T4 were noted, clinically significant drug-induced thyroid dysfunction was rare. Expectedly, researchers saw significant elevations in SHBG (Sex Hormone-Binding Globulin), a functional pharmacodynamic (PD) marker confirming on-target THR-β activation.
Low Risk of DILI: First-generation THR systemic toxicity (osteoporosis, cardiotoxicity, hepatotoxicity) via THR-α or poor targeting was successfully avoided.

5. Implications for Next-Generation Pipelines (Competitors)

Every MASH pipeline advancing towards Phase 2 or Phase 3 (such as FGF21 analogues and GLP-1 multi-agonists) will no longer be compared merely against a placebo. They must now compete against Resmetirom as the "Standard of Care."

Hurdle 1: How to beat the numbers? "~30% NASH resolution" and "~25% Fibrosis improvement." Unless a new drug can deliver overwhelmingly superior numbers—particularly in "fibrosis reversal"—capturing market share will be exceptionally difficult (See: The Frontline of Liver Anti-Fibrotic Drug Development 2026).
Hurdle 2: Convenience. Resmetirom is a once-daily oral tablet. How will injectable treatments (like many peptide-based incretins) maintain long-term patient compliance against a daily pill?

6. Conclusion: FDA Indication Limits & The Future

The success of the MAESTRO-NASH trial is a testament to matching the "right target (THR-β)" with a "meticulously designed clinical trial protocol."

Importantly, the FDA label strictly limits Rezdiffra's indication to adult patients with noncirrhotic MASH and moderate to advanced liver fibrosis (consistent with stages F2 to F3). It is explicitly not indicated for patients with F4 (cirrhosis, compensated or decompensated). Furthermore, its OATP1B1/1B3 mechanism necessitates dosage warnings when co-administered with statins. In particular, the extensive use of Non-Invasive Tests (NITs, like MRI-PDFF) for patient screening will serve as a textbook model for all future MASH trials.

From a preclinical CRO perspective, a new mandatory package for MASH drug discovery is emerging: "Placing Resmetirom (or a closely related proxy) as an active positive control in animal studies, and explicitly proving your compound's superiority."

References & Clinical Trials

1. Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. 2. Harrison SA, et al. MAESTRO-NAFLD-1. Nat Med. 2023;29(11):2919-2928. 3. Keitel V, Kannt A. Resmetirom for the treatment of NASH/MASH. Metabolism. 2024;154:155835. 4. Kannt A, et al. Thyroid hormone receptor-β agonist resmetirom decreases steatosis and fibrosis in a preclinical model of NASH. Br J Pharmacol. 2021;178(12):2412-2423. 5. FDA. Rezdiffra (resmetirom) Prescribing Information. 2024.